B+
Bull case
25%
Probability
Target price
$4.75
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
TLSI
TriSalus Life SciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The better read-through from Q1 is that the core platform still showed 86.2% gross margin, cash rose to $56.6 million after the $46 million raise, and management kept layering real-world PEDD evidence plus a visible second-half data calendar. If the commercial reset was genuinely temporary and TriNav Advance clears in 2H26, the current equity value leaves room for a sharper rerating than a normal medtech quarter would imply [#PR-2026-05-12].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
2026 revenue guidance was reduced to $54 million-$57 million after Q1 revenue of $8.9 million missed the prior growth trajectory.
Momentum
66
Value
41
Sentiment
38
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.10 · Bull $4.75 · Bear $1.50Analysis 2026-05-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $10.40
Why
Momentum66 · Δ7d -
Value41 · Δ7d -0.0
Sentiment38 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • 2026 revenue guidance was reduced to $54 million-$57 million after Q1 revenue of $8.9 million missed the prior growth trajectory.
- • Commercial expansion doubled territory capacity but disrupted Q1 sales; if rep productivity ramps slower than expected, Q3/Q4 recovery could disappoint.
- • The harder read-through is that revenue fell, the 2026 guide was cut, and management tied the reset to both self-inflicted sales disruption and a meaningful FDA timing slip for TriNav Advance.
Catalyst clock
2026-08-15
Second-half revenue recovery must offset the Q1 reset
Lead driver: Value · See fundamentals
Momentum
66
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
38
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 65.5 / Value 40.6 / Sentiment 37.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$3.10
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$233.98M
Beta
0.43
Shares Out
61.57M
P/E (TTM) · Derived
-2.1
P/S (TTM)
7.59
P/FCF (TTM) · Derived
-8.31
Rev YoY
+1.7%
EPS YoY
-42.4%
Gross Margin
+85.8%
Op Margin
-67.7%
Net Debt
$14M
Current Ratio
5.35
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data